Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker JNJ · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult… NCT04513912 · Depressive Disorder, Major Seltorexant, Matching placebo to Seltorexant | JNJ Janssen Research & Development, LLC | Phase 3 | Completed | 757 | Oct 3, 2023 | Registry ↗ |
| Nov 12, 2026 | INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock W… NCT06965504 · Heart Failure, Cardiogenic Shock Impella 5.5 SmartAssist | JNJ Abiomed Inc. | Not applicable | Recruiting | 250 | Dec 1, 2028 | Registry ↗ |
| Nov 12, 2026 | Nipocalimab in Moderate to Severe Sjogren's Disease NCT06741969 · Sjogrens Syndrome Nipocalimab, Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 655 | Feb 4, 2027 | Registry ↗ |
| Nov 12, 2026 | Abiomed Impella RT-DAQ - Observational Study NCT06308055 · Cardiogenic Shock Data Acquisition | JNJ Abiomed Inc. | — | Recruiting | 125 | Jun 30, 2027 | Registry ↗ |
| Nov 12, 2026 | REDUCER-I: An Observational Study of the Neovasc Reducer™ System NCT02710435 · Angina Pectoris, Angina Pectoris, Stable Reducer System | JNJ Shockwave Medical, Inc. | — | Active, not recruiting | 400 | Nov 2023 | Registry ↗ |
| Nov 9, 2026 | A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus… NCT07735793 · Urinary Bladder Neoplasms | JNJ Janssen Korea, Ltd., Korea | — | Recruiting was not yet recruiting | 1 | Nov 23, 2026 | Registry ↗ |
| Nov 6, 2026 | Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal NCT07788521 · Visual Acuity Senofilcon A, Nelfilcon A | JNJ Johnson & Johnson Vision Care, Inc. | Not applicable | Recruiting | 150 | Dec 11, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of HARMONIC 700 Shears With Advanced Hemostasis in Pediatric and Adult Surgical Procedures NCT06608485 · Pediatric Surgical Procedures, Adult Surgical Procedures HARMONIC 700 Shears | JNJ Ethicon Endo-Surgery | — | Completed | 173 | Jun 30, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) NCT04968912 · Sjogren's Syndrome Placebo, Nipocalimab | JNJ Janssen Research & Development, LLC | Phase 2 | Completed | 163 | Oct 23, 2023 | Registry ↗ |
| Nov 5, 2026 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis NCT04951622 · Myasthenia Gravis Nipocalimab, Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Recruiting | 199 | Nov 17, 2023 | Registry ↗ |
| Nov 5, 2026 | A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease NCT04619420 · Alzheimer Disease, Cognitive Dysfunction JNJ-63733657, Placebo | JNJ Janssen Research & Development, LLC | Phase 2 | Terminated | 523 | Oct 17, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to Nipocalimab NCT07915232 · Pregnancy Related, Pregnancy | JNJ Janssen Research & Development, LLC | — | Not yet recruiting | 162 | Apr 30, 2036 | Registry ↗ |
| Nov 4, 2026 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalid… NCT07903272 · Multiple Myeloma Ramantamig, Daratumumab | JNJ Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | 1,000 | Jan 11, 2037 | Registry ↗ |
| Nov 4, 2026 | A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent At… NCT07845682 · Atrial Fibrillation Radiofrequency/Pulsed Field Ablation | JNJ Biosense Webster, Inc. | Not applicable | Recruiting was not yet recruiting | 150 | Apr 17, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatmen… NCT07727057 · Arrhythmias, Cardiac Radiofrequency/Pulsed Field Ablation System | JNJ Biosense Webster, Inc. | Not applicable | Recruiting | 90 | Sep 30, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized S… NCT07511166 · Atrial Fibrillation | JNJ Johnson & Johnson Medical (Shanghai) Ltd. | — | Recruiting was not yet recruiting | 300 | Jul 28, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants Wi… NCT07429214 · Atrial Fibrillation Pulsed Field Ablation System | JNJ Biosense Webster, Inc. | Not applicable | Active, not recruiting | 42 | Dec 30, 2026 | Registry ↗ |
| Nov 4, 2026 | A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation… NCT07227532 · Atrial Fibrillation Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE G… | JNJ Biosense Webster, Inc. | Not applicable | Recruiting | 276 | Dec 31, 2030 | Registry ↗ |
| Nov 4, 2026 | A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter NCT07116525 · Scar-related Atrial Tachycardia, Persistent Atrial Fibrilla… Paddle-Shaped, High-Density, Multi-Electrode Mapping Cathet… | JNJ Biosense Webster, Inc. | Not applicable | Recruiting | 90 | Feb 7, 2027 | Registry ↗ |
| Nov 4, 2026 | Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process NCT06967129 · Astigmatism Investigational daily disposable, soft, toric lenses manufa… | JNJ Johnson & Johnson Vision Care, Inc. | Not applicable | Completed | 281 | Jul 14, 2025 | Registry ↗ |
| Nov 4, 2026 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B… JNJ-75348780, JNJ-67856633 | JNJ Janssen Research & Development, LLC | Phase 1 | Enrolling by invitation | 120 | Jan 19, 2028 | Registry ↗ |
| Nov 4, 2026 | Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Wee… NCT06749496 · Astigmatism Test Lens, Control Lens | JNJ Johnson & Johnson Vision Care, Inc. | Not applicable | Completed | 134 | Mar 20, 2025 | Registry ↗ |
| Nov 4, 2026 | EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) NCT06631638 · Osteoarthritis, Traumatic Arthritis EMPHASYS Cup with VHN | JNJ DePuy Orthopaedics | Not applicable | Recruiting | 118 | Dec 31, 2027 | Registry ↗ |
| Nov 4, 2026 | The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety… NCT06510205 · Breast Augmentation, Mammaplasty Mentor Breast implants | JNJ Johnson & Johnson Medical (Shanghai) Ltd. | — | Recruiting | 6,111 | Jun 30, 2034 | Registry ↗ |
| Nov 4, 2026 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis… NCT06220604 · Plaque Psoriasis JNJ-77242113, JNJ-77242113 Matching Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 731 | Nov 15, 2024 | Registry ↗ |
| Nov 4, 2026 | A Study of JNJ-87890387 for Advanced Solid Tumors NCT06178614 · Neoplasms, Advanced Solid Tumors JNJ-87890387 | JNJ Janssen Research & Development, LLC | Phase 1 | Recruiting | 200 | Mar 16, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplas… NCT06150157 · Neoplasms JNJ-88549968, Ruxolitinib | JNJ Janssen Research & Development, LLC | Phase 1 | Recruiting | 300 | Jun 14, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis NCT06143878 · Plaque Psoriasis JNJ-77242113, JNJ-77242113 Matching Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 774 | Sep 17, 2024 | Registry ↗ |
| Nov 4, 2026 | A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psorias… NCT06095115 · Plaque Psoriasis JNJ-77242113, Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 684 | Jul 29, 2024 | Registry ↗ |
| Nov 4, 2026 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or C… NCT05572515 · Multiple Myeloma Teclistamab, Pomalidomide | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 614 | Oct 13, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis NCT05528510 · Colitis, Ulcerative Guselkumab Dose 1, Guselkumab Dose 2 | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 418 | Apr 2, 2024 | Registry ↗ |
| Nov 4, 2026 | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies NCT05379634 · Myositis Nipocalimab, Placebo | JNJ Janssen Research & Development, LLC | Phase 2 | Completed was active, not recruiting | 36 | Sep 4, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis NCT05265273 · Myasthenia Gravis Nipocalimab | JNJ Janssen Research & Development, LLC | Phase 2/3 | Recruiting | 12 | Jun 30, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Sev… NCT05242484 · Colitis, Ulcerative Guselkumab, Golimumab | JNJ Janssen Research & Development, LLC | Phase 2 | Active, not recruiting | 577 | May 15, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Sev… NCT05242471 · Crohn's Disease Guselkumab, Golimumab | JNJ Janssen Research & Development, LLC | Phase 2 | Active, not recruiting | 703 | May 23, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With… NCT04988295 · Carcinoma, Non-Small-Cell Lung Lazertinib, Amivantamab | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 776 | Jul 10, 2023 | Registry ↗ |
| Nov 4, 2026 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis NCT04882098 · Arthritis, Psoriatic Guselkumab, Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 1,054 | Dec 30, 2024 | Registry ↗ |
| Nov 4, 2026 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) NCT04811560 · Acute Leukemia Bleximenib | JNJ Janssen Research & Development, LLC | Phase 1/2 | Recruiting | 420 | Dec 29, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acet… NCT04497844 · Prostatic Neoplasms Niraparib+ Abiraterone acetate fixed dose combination (FDC)… | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 696 | Jan 7, 2025 | Registry ↗ |
| Nov 4, 2026 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or… NCT04487080 · Carcinoma, Non-Small-Cell Lung Amivantamab, Osimertinib | JNJ Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | 1,074 | Aug 11, 2023 | Registry ↗ |
| Nov 4, 2026 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive S… NCT04325828 · Salivary Gland Neoplasms Apalutamide, GnRH Agonist | JNJ Janssen Pharmaceutical K.K. | Phase 2 | Active, not recruiting | 31 | Jun 9, 2021 | Registry ↗ |
| Nov 4, 2026 | A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis NCT04033445 · Ulcerative Colitis Placebo, Guselkumab | JNJ Janssen Research & Development, LLC | Phase 2/3 | Active, not recruiting | 1,064 | Sep 19, 2023 | Registry ↗ |
| Nov 3, 2026 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer NCT07906717 · Prostatic Neoplasms JNJ-101556143, Placebo | JNJ Janssen Research & Development, LLC | Phase 3 | Recruiting was not yet recruiting | 400 | Feb 14, 2028 | Registry ↗ |
| Nov 3, 2026 | A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea NCT07890285 · Pulmonary Arterial Hypertension | JNJ Janssen Korea, Ltd., Korea | — | Not yet recruiting | 333 | Oct 29, 2032 | Registry ↗ |
| Nov 3, 2026 | A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease… NCT07848737 · Colitis, Ulcerative, Crohn Disease | JNJ Janssen-Cilag, S.A. | — | Not yet recruiting | 200 | Jun 30, 2029 | Registry ↗ |
| Nov 3, 2026 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer NCT07832292 · Prostatic Neoplasms JNJ-101556143 | JNJ Janssen Research & Development, LLC | Phase 2 | Recruiting | 100 | May 17, 2029 | Registry ↗ |
| Nov 3, 2026 | A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease NCT07822529 · Inflammatory Bowel Diseases | JNJ Janssen Research & Development, LLC | — | Recruiting | 400 | Jan 1, 2030 | Registry ↗ |
| Nov 3, 2026 | Evaluation of Approved Contact Lenses (CR-6657) NCT07819305 · Visual Acuity Test (Senofilcon A), Control (Serafilcon A) | JNJ Johnson & Johnson Vision Care, Inc. | Not applicable | Active, not recruiting was recruiting | 145 | Dec 3, 2026 | Registry ↗ |
| Nov 3, 2026 | A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With t… NCT07788989 · Atrial Fibrillation VARIPULSE Catheter System (PVI), VARIPULSE Catheter System… | JNJ Biosense Webster, Inc. | Not applicable | Not yet recruiting | 2,300 | Oct 31, 2029 | Registry ↗ |
| Nov 3, 2026 | A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis… NCT07746765 · Crohn Disease, Colitis, Ulcerative | JNJ Janssen Sciences Ireland UC | — | Not yet recruiting | 35 | Aug 3, 2029 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances